Chapters

Transcript

Video

What are the unique elements of the trial design for the CAHtalyst trial, which evaluated crinecerfont in children and adolescents for the treatment of congenital adrenal hyperplasia?

What are the unique elements of the trial design for the CAHtalyst trial, which evaluated crinecerfont in children and adolescents for the treatment of congenital adrenal hyperplasia?


Created by

CMEducation Resources | iQ&A Congenital Adrenal Hyperplasia (CAH) Medical Intelligence Zone 

Presenter

Patricia Fechner, MD

Patricia Fechner, MD

Medical Director, DSD Program
Medical Director, CAH Program
Co-Director, Turner Syndrome Clinic
Seattle Children’s Hospital
Professor of Pediatrics
University of Washington School of Medicine
Seattle, WA